Department of Surgery, Kameda Medical Center, 929 Higashi-cho, Kamogawa, Chiba, 296-8602, Japan.
Int J Clin Oncol. 2010 Jun;15(3):280-6. doi: 10.1007/s10147-010-0059-4. Epub 2010 Mar 16.
We carried out this study to examine the health-related quality of life (HRQOL) of patients with advanced colorectal cancer treated with the oral fluoropyrimidine S-1 plus irinotecan (CPT-11).
HRQOL was assessed at baseline (pretreatment) and at 5-week intervals during treatment, using the European Organization for Research and Treatment of Cancer QLQ-C30 and QLQ-CR38 questionnaires. The HRQOL data for 12 preselected scales and 21 courses of treatment were then analyzed longitudinally.
Thirty-seven patients completed the baseline and post-treatment HRQOL assessments. Statistically significant differences between the baseline and post-treatment HRQOL scores were observed for the global QOL, social function, and pain scales (all QLQ-C30), as well as the body image, future perspective, gastrointestinal tract symptoms, weight loss, and chemotherapy side effects scales (all QLQ-CR38); favorable post-treatment results were observed for all the scales except for body image and chemotherapy side effects, for which post-treatment deteriorations were observed. The changes in body image, future perspective, weight loss, and chemotherapy side effects were each greater than ten points and seemed clinically significant.
Combined treatment with S-1 plus CPT-11 resulted in an acceptable deterioration in HRQOL functioning and symptoms, compared with baseline levels.
我们开展这项研究，旨在考察接受口服氟嘧啶 S-1 联合伊立替康（CPT-11）治疗的晚期结直肠癌患者的健康相关生活质量（HRQOL）。
使用欧洲癌症研究与治疗组织（EORTC）的 QLQ-C30 和 QLQ-CR38 问卷，在基线（治疗前）和治疗期间每 5 周评估一次 HRQOL。然后对 12 个预选量表和 21 个疗程的 HRQOL 数据进行纵向分析。
37 例患者完成了基线和治疗后 HRQOL 评估。在全球 QOL、社会功能和疼痛量表（所有 QLQ-C30）以及身体形象、未来展望、胃肠道症状、体重减轻和化疗副作用量表（所有 QLQ-CR38）方面，基线和治疗后 HRQOL 评分均存在统计学显著差异；除身体形象和化疗副作用外，所有量表的治疗后结果均较好，而身体形象和化疗副作用的治疗后恶化。身体形象、未来展望、体重减轻和化疗副作用的变化均大于 10 分，似乎具有临床意义。
与基线水平相比，S-1 联合 CPT-11 治疗导致 HRQOL 功能和症状可接受的恶化。
